Organigram Global Inc. (OGI) shares climbed Thursday morning after the cannabis company locked down a 65.2 million Canadian dollar private placement from British American Tobacco's (BTI) subsidiary, effectively greenlighting its European expansion plans.

The funding breakthrough answers the question investors have been asking: how exactly will Organigram pay for its ambitious Sanity Group acquisition? Now we know.

How the Deal Breaks Down

British American Tobacco's subsidiary is subscribing to 14,027,074 shares at 3.00 Canadian dollars each, putting 42.08 million Canadian dollars on the table. Add in the exercise of top-up rights for another 9,897,356 shares at 2.335854 Canadian dollars per share (worth 23.12 million Canadian dollars), and you get 65.2 million Canadian dollars in total gross proceeds.

This isn't just abstract numbers. The money directly addresses the funding gap for Organigram's proposed acquisition of Sanity Group GmbH. The proceeds will cover the cash portion of the 113.4 million euro upfront consideration, plus transaction expenses and general working capital needs.

Wednesday's hint that advanced negotiations were underway has now become Thursday's reality. That quick progression from "we're talking" to "it's done" suggests both parties were eager to get this across the finish line.

Why This Matters Beyond the Dollars

The confirmed investment does two things simultaneously. First, it strengthens Organigram's balance sheet in a concrete way. Second, and perhaps more importantly, it signals continued backing from British American Tobacco, which already holds stakes in both Organigram and Sanity.

That alignment isn't coincidental. BAT's willingness to deepen its involvement reinforces confidence in the strategic logic of building a global pure-play cannabis platform with meaningful exposure to key European markets. When your major shareholder puts more money in rather than sitting on the sidelines, that's usually a good sign.

What the Charts Are Saying

The stock is trading 4.8% above its 20-day simple moving average but 6.2% below its 100-day SMA. Translation: short-term momentum looks decent, but longer-term challenges remain visible. Shares have gained 4.55% over the past 12 months and sit closer to their 52-week lows than highs, reflecting cautious market sentiment that hasn't fully embraced the growth story yet.

The RSI stands at 41.29, which qualifies as neutral territory. The stock is neither overbought nor oversold right now. Meanwhile, the MACD sits at -0.0919, below its signal line at -0.0735, pointing to bearish pressure.

Put it together and you get mixed momentum. The neutral RSI combined with a bearish MACD suggests traders should watch for potential shifts in market sentiment before making aggressive moves.

• Key Resistance: $2.00
• Key Support: $1.50

Looking Ahead to Earnings

Organigram is scheduled to report its next financial results on May 11, 2026. Analysts are expecting a loss of 1 cent per share, down from 22 cents previously, alongside revenue of $54.67 million, up from $45.70 million. The company trades at a P/E ratio of 12.2x, which suggests a potential value opportunity for investors willing to bet on the European expansion thesis.

OGI Price Action: Organigram Global shares were up 8.70% at $1.50 during premarket trading on Thursday.